We also show that losartan, an AT1R blocker, does not attenuate development of hepatic steatosis in HFD-fed mice, indicating that the effect of PRR antagonism in hepatic steatosis is probably RAS-independent. Here, ATP6AP2 is linked to Hepatic steatosis.